SHP2
4 articles
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Covalent fragments reach lysines in the SHP2 allosteric latch site
- Combines an electrophile-first covalent fragment screen with a ligand-first strategy to target lysines in the allosteric latch site of SHP2 phosphatase.
- Computational and experimental analyses support the binding mode, and the work yields what the authors call the first potent, cell-active allosteric covalent inhibitors at this site.
- It shows the latch site is covalently tractable, opening routes to new allosteric SHP2 chemotypes.
Lysine-directed covalent chemistry is far rarer than cysteine, so a workflow that actually delivers cell-active hits on a lysine is the takeaway, more than SHP2 itself. My caveat is reactivity versus stability: lysine electrophiles can be hydrolytically fragile or reversible, so I'd want proteome-wide selectivity data before calling anything a probe.
Medicinal ChemistrychemRxiv
Can ternary-complex scoring rank close PROTAC linker analogues? A matched-pose test
- Linker optimization in targeted protein degradation is still largely empirical.
- The preprint asks whether current computational methods can rank close linker analogues before synthesis, the finest chemical differences yet tested.
- It uses a matched-pose design on VHL-recruiting SHP2 degraders to isolate the effect of the linker.
- This is a preprint, not yet peer reviewed; the snippet-level abstract available limits detail on the outcome.
Linker tweaks are where PROTAC campaigns burn months of synthesis, so an honest test of whether scoring can separate near-identical analogues is more useful than another headline-grabbing benchmark. Matched poses remove the usual excuse that the method just got the geometry wrong. Even a negative answer helps: it tells us to keep building degradation and cooperativity assays rather than trusting a docked score.
Medicinal ChemistrychemRxiv
Chemists Report New Allosteric SHP2 Inhibitors Built on an Azaindole Scaffold
- SHP2 is a cytosolic protein tyrosine phosphatase implicated in oncogenic RTK and immune checkpoint signaling, making it a closely watched cancer/immuno-oncology target.
- Earlier allosteric SHP2 inhibitors have reached clinical trials but can face resistance mutations or PK limitations, motivating further chemotype exploration.
- This preprint reports a new series of N-aryl-1H-azaindole-derived allosteric SHP2 inhibitors, shifting away from orthosteric (active-site) inhibition approaches.
That shallow, conserved catalytic pocket is exactly why orthosteric SHP2 programs never went anywhere in my hands—no surprise this moves allosteric. But the irony's real: clinical allosteric inhibitors like TNO155 already picked up resistance mutations right in that allosteric tunnel, so a new chemotype needs to show it escapes those hotspots, not just re-occupy the same pocket with a different scaffold.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Lysine-Targeted Covalent Fragments Open a New Allosteric Route to Inhibit SHP2
- Researchers built a combined screening pipeline pairing covalent fragment screening with a ligand-first design strategy to find chemical matter that reacts with lysine side chains rather than the more commonly targeted cysteines.
- The work focuses on the allosteric "latch" region of SHP2 phosphatase, a regulatory site distinct from the enzyme's catalytic pocket and from previously drugged allosteric tunnel sites.
- Computational modeling and experimental characterization were used together to guide fragment selection and to understand how covalent attachment at latch-site lysines affects the protein's conformational behavior.
- The approach yielded inhibitors described as the first potent, cell-active covalent compounds acting through this latch site, indicating the pocket can support functional, drug-like engagement rather than only structural characterization.
- The findings position lysine-directed covalent chemistry as a viable route for allosteric SHP2 modulation and provide a starting chemotype and site for further medicinal chemistry optimization.
Lysine-directed covalency is the real bet here, more than the new pocket itself: warhead chemistry and selectivity triage are far less mature than for cysteine acrylamides, so the first thing I'd pull up is proteome-wide lysine reactivity data before trusting the cell activity. The latch site itself is also genuinely new — it sits apart from where SHP099/TNO155-type allosteric inhibitors already bind, so this isn't retreading crowded IP. Getting cell-active hits straight out of fragment screening is a strong signal for this pocket's shape or a hyperreactive lysine — but fragment-to-lead on Lys chemistry means slower SAR cycles than we're used to with Cys warheads. Real value: a fresh chemotype and site for a target whose allosteric space was starting to feel exhausted.